Vehreschild, Maria J. G. T.
Taori, Surabhi
Goldenberg, Simon D.
Thalhammer, Florian
Bouza, Emilio
van Oene, Joop
Wetherill, Graham
Georgopali, Areti
Funding for this research was provided by:
Astellas Pharma Europe B.V.
Astellas Pharma, Inc
Article History
Received: 19 June 2018
Accepted: 2 August 2018
First Online: 11 August 2018
Change Date: 8 November 2018
Change Type: Correction
Change Date: 8 November 2018
Change Type: Correction
Change Details: The article “Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)”, written by M.J.G.T. Vehreschild et al., was originally published at Springerlink on 11 August 2018 without open access.
Change Details: The article ?Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)?, written by M.J.G.T. Vehreschild et al., was originally published at Springerlink on 11 August 2018 without open access.
Compliance with ethical standards
:
: Maria JGT Vehreschild is a consultant to Astellas Pharma, Berlin Chemie, Maat Pharma and MSD/Merck; has served at the speakers’ bureaux of Astellas Pharma, Basilea, Falk Foundation, Gilead Sciences, Merck/MSD, Organobalance and Pfizer; and received research funding from 3M, Astellas Pharma, DaVolterra, Gilead Sciences, Merck/MSD, Morphochem, Organobalance and Seres Therapeutics. Surabhi Taori has received conference attendance sponsorship and speaker fees from Astellas Pharma, Inc. Simon D. Goldenberg has received consultancy fees from Astellas, Pfizer and MSD; speaker fees from Astellas and MSD; and research funding from Astellas. Joop van Oene is a full-time employee of Astellas Pharma Europe B.V. Graham Wetherill is a consultant statistician for Astellas Pharma Europe B.V. Areti Georgopali is a full-time employee of Astellas Pharma, Inc. Florian Thalhammer and Emilio Bouza have no conflicts of interest to declare.
: This study was conducted in accordance with the Declaration of Helsinki and with the approval of the Independent Ethics Committee/Institutional Review Board of each country and site, where required. This was a retrospective study and all patient data were anonymised; informed consent was therefore not required under country-specific regulations. No direct access to source data by the clinical research organisation or the sponsor was allowed.